magnifying glass
logo for Zenas BioPharma

Zenas BioPharma

Business Services · <25 Employees

Get Full Access

Who is Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and commercialization of immune-based therapies for patients in the US, China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases.Read More

Revenue

Revenue:

<$5 Million
Zenas BioPharma's Social Media
SIC Code 80,283
NAICS Code 325,3254
Popular Searches:

Zenas BioPharma

Zenas BioPharma LLC

Zenas

Zenas BioPharma's Org Chart

PhonePhoneEmailEmail
Heidi Kempinski
Heidi Kempinski

Chief Operating Officer (USA)

PhonePhoneEmailEmail
Joseph Farmer
Joseph Farmer

President & Chief Operating Officer

PhonePhoneEmailEmail

PhonePhoneEmailEmail
Illustration of an envelope

Zenas BioPharma's Tech Stack

PHP

By

PHP

Google Global Site Tag

By

Google

reCAPTCHA

By

Google

Twitter Cards

By

Twitter
See more technologies

Zenas BioPharma News & Media

Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease

WALTHAM, Mass. and SHANGHAI, China, May 15, 2022 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the submission of an investigational new drug (IND) application to the China National Medical Products Administration (NMPA) for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (T

Zenas BioPharma Appoints Dr. John Orloff to Board of Directors

BOSTON and SHANGHAI, China, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and delivery of immune-based therapies, today announced the appointment of John Orloff, MD to its Board of Directors. Dr. Orloff joins the Zenas Board with over 25 years of experience successfully leading global research and development organizations across multiple therapeutic areas including autoimmune diseases.

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

MONROVIA, Calif., HONG KONG & BOSTON--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas BioPharma (“Zenas”), a global biopharmaceutical company based in the USA and China committed to the development and delivery of immune-based therapies, today announced that Zenas has acquired from Xencor exclusive worldwide rights to develop, manufact
Subscribe to "Zenas BioPharma" News

Frequently Asked Questions regarding Zenas BioPharma

What is Zenas BioPharma’s official website?

Zenas BioPharma’s official website is www.zenasbio.com

What is Zenas BioPharma’s Revenue?

Zenas BioPharma’s revenue is <$5 Million

What is Zenas BioPharma’s SIC code?

Zenas BioPharma’s SIC: 80,283

What is Zenas BioPharma’s NAICS code?

Zenas BioPharma’s NAICS: 325,3254

How many employees are working in Zenas BioPharma?

Zenas BioPharma has <25 employees

What is Zenas BioPharma’s industry?

Zenas BioPharma is in the industry of: Business Services, Research & Development, Chemicals & Related Products

What is Zenas BioPharma's tech stack?

The technologies that are used by Zenas BioPharma are: PHP, Google Global Site Tag, reCAPTCHA, Twitter Cards

See more information about Zenas BioPharma
4.4/5 on G2 Crowd